ProCE Banner Activity

How Can We Screen for and Identify Tardive Dyskinesia?

Podcast Episodes

Listen to 2 thought leaders in the psychiatry field discuss the importance of screening for tardive dyskinesia in patients receiving antipsychotics, including clinical pearls for identification in various clinical settings.

Released: July 13, 2022

Expiration: July 12, 2023

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Greg W. Mattingly, MD

Associate Clinical Professor

Department of Psychiatry

Washington University School of Medicine

President

St. Charles Psychiatry Associates

St. Louis, Missouri

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Greg W. Mattingly, MD

Associate Clinical Professor

Department of Psychiatry

Washington University School of Medicine

President

St. Charles Psychiatry Associates

St. Louis, Missouri

Greg W. Mattingly, MD: consultant: AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, Teva; non-CME/CE services: AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Trispharma.

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Jonathan M. Meyer, MD: consultant: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America Inc., Sunovion Pharmaceuticals, Teva Pharmaceuticals.